Full Year Revenue up 25%
Full Year Earnings per Share $0.13 Compared to Loss of $0.16 in
Prior Year
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for
its fourth quarter and fiscal year ending June 30, 2015.
Fourth Quarter Results
Net revenues for the fourth quarter of fiscal 2015 rose approximately
13% to $5.2 million, compared to $4.6 million in the same quarter of
fiscal 2014. Growth in total net revenues was attributable to strong
results in the home care market where revenue increased by approximately
11.8%, or $0.5 million, compared to the same period of fiscal 2014. Home
care sales increased due to a greater number of approvals and a higher
average selling price from third party payers, such as insurance
companies, Medicare and Medicaid, for the Company’s SmartVest®
products. Broader sales coverage and more focused territory management
also contributed to the sales increase.
The Company reported net income of $255,000, or $0.03 cents per basic
and diluted share, for the fourth quarter of fiscal 2015, compared to
$290,000, or $0.04 per basic and diluted share, for the same period of
fiscal 2014. Net income in the fourth quarter of fiscal 2015 was
affected by an increase in our current tax expenses as we fully utilized
our federal net operating loss carryforwards and by a reserve on certain
SV2100 inventory parts, that may no longer be utilized in production, of
$110,000, due to achieving additional cost reductions that will lower
the cost of our newer SmartVest SQL to a cost significantly lower than
our previous products and that will shorten the length of time that we
phase out sales of our SV2100 product.
Gross margins in the fourth quarter of fiscal 2015 were 72.0%, up from
70.1% in the fourth quarter of fiscal 2014. The increase in gross profit
percentage resulted primarily from the increase in domestic home care
revenue at higher average selling price and greater referral to approval
percentage, as compared with the same period in the prior year.
Operating expenses, which include selling, general and administrative as
well as research and development expenses, in the fourth quarter of
fiscal 2015, were $3.3 million or 64.2% of revenue compared with $2.9
million or 62.3% of revenue in the same period of the prior year. The
increase was due primarily to higher sales commission expense,
recruiting costs for additional salespeople and consulting fees for
sales training and information technology improvements.
Commenting on the fourth quarter results, Kathleen Skarvan, President
and Chief Executive Officer of the Company said, “We are pleased to
report another solid quarter of revenue growth and increased
profitability. Execution across the Company continued to improve and we
are seeing the results of our commitment to achieving consistently
higher referral to approval percentages, lower manufacturing costs and
best-in-class patient service. Our improved profitability also
contributed to strong cash flow from operations of nearly $1 million in
the fourth quarter and we ended the quarter with $3.6 million in cash.”
Full Year Results
Net revenues for the fiscal year ended June 30, 2015 were $19.4 million,
an increase of 25% compared with the previous year. Net income was $1.1
million, or $0.13 per basic and diluted share compared with a net loss
of $1.3 million, or $0.16 per basic and diluted share, in the previous
year. The fiscal 2014 loss included a full valuation allowance against
all the Company’s net U.S. federal and state deferred tax assets
totaling $727,000 which offset expected tax benefits and resulted in a
tax expense of $469,000 for the year.
The higher revenue in fiscal 2015 was the result of higher sales in both
the home care and institutional markets. Home care, which accounted for
about 86% of total revenue, increased 28% and institutional rose 22%
compared with fiscal 2014. The increase resulted primarily from higher
approval rates on referrals, higher average selling price and an
increase in the total number of referrals. Referrals are prescriptions
for our products from a physician for a patient and the approvals are
from third-party payer organizations including Medicare, Medicaid and
private insurance providers.
Gross profit for fiscal 2015 was $13.6 million, or 70.1% of net revenue,
compared with 68.7% in the prior year. The increase was the result of
higher net revenues and higher average selling prices. Gross margin for
2015 was negatively impacted by a write-off and reserves for obsolete
inventory and tooling. Operating expenses were $12.3 million or 63.3% of
net revenues, in fiscal 2015, compared with $11.4 million, or 73.4% of
revenues, in the prior year. The decline in expenses as a percentage of
net revenues was primarily due to the higher level of revenues in fiscal
2015 as well as careful alignment of spending with opportunities. The
Company expects its revenues to continue to grow faster than expenses in
fiscal 2016. Cash flow from operations was $2.8 million in fiscal 2015,
compared with $2.1 million in the prior year.
Commenting on the full year results, Ms. Skarvan said, “Fiscal 2015 was
an important year for Electromed as we demonstrated revenue growth year
over year, achieved four profitable quarters and delivered solid cash
flow and earnings per share. The emphasis we placed on aligning the
Company to compete in the current and future healthcare environment by
improving our reimbursement process, lowering manufacturing costs and
upgrading sales execution has begun to pay off. I am grateful for our
dedicated team of employees for their focus on patient care and
satisfaction, an essential component of our success. Looking ahead, we
believe the market for high frequency chest wall oscillation products is
poised to grow as more patients, especially older ones, are diagnosed
with breathing issues for which HFCWO is a proven therapy option. We
have excellent product offerings and a strong team to take advantage of
these opportunities. The Company’s balance sheet is strong and we have
the financial resources in place to grow as the market unfolds.”
About Electromed, Inc.
Electromed, Inc. develops,
manufactures, markets, and sells innovative products that provide airway
clearance therapy, including the SmartVest® Airway Clearance
System and related products, to patients with compromised pulmonary
function with a commitment to excellence and compassionate service.
Further information about the Company can be found at www.electromed.com.
Cautionary Statements
Certain statements found in this release may constitute
forward-looking statements as defined in the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements reflect the
speaker’s current views with respect to future events and financial
performance and include any statement that does not directly relate to a
current or historical fact. Forward-looking statements can generally be
identified by the words “anticipate,” “believe,” “expect,” “will” and
similar words. Forward-looking statements made in this release
include the Company’s beliefs regarding continued progress in its
reimbursement, revenue growth and cost control strategies, expectations
for market growth, available financial resources. Forward-looking
statements cannot be guaranteed and actual results may vary materially
due to the uncertainties and risks, known and unknown, associated with
such statements. Examples of risks and uncertainties for the Company
include, but are not limited to, the impact of emerging and existing
competitors, the effect of new legislation on our industry and business,
the effectiveness of our sales and marketing and cost control
initiatives, changes to reimbursement programs, as well as other factors
described from time to time in our reports to the Securities and
Exchange Commission (including our Annual Report on Form 10-K).
Investors should not consider any list of such factors to be an
exhaustive statement of all of the risks, uncertainties or potentially
inaccurate assumptions investors should take into account when making
investment decisions. Shareholders and other readers should not place
undue reliance on “forward-looking statements,” as such statements speak
only as of the date of this release.
Financial Tables Follow:
Electromed, Inc.
|
|
|
|
|
Condensed Balance Sheets
|
|
|
|
|
|
|
|
|
|
|
|
June 30,
|
|
June 30,
|
|
|
2015
|
|
2014
|
Assets
|
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
Cash
|
|
$
|
3,598,240
|
|
|
$
|
1,502,702
|
|
Accounts receivable (net of allowances for doubtful accounts of
$45,000)
|
|
|
6,518,816
|
|
|
|
6,487,267
|
|
Inventories
|
|
|
2,072,108
|
|
|
|
2,235,496
|
|
Prepaid expenses and other current assets
|
|
|
397,833
|
|
|
|
397,853
|
|
Total current assets
|
|
|
12,586,997
|
|
|
|
10,623,318
|
|
Property and equipment, net
|
|
|
3,635,516
|
|
|
|
3,935,802
|
|
Finite-life intangible assets, net
|
|
|
999,842
|
|
|
|
1,039,413
|
|
Other assets
|
|
|
182,699
|
|
|
|
193,633
|
|
Total assets
|
|
$
|
17,405,054
|
|
|
$
|
15,792,166
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareholders’ Equity
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
Current maturities of long-term debt
|
|
$
|
48,749
|
|
|
$
|
46,375
|
|
Accounts payable
|
|
|
538,518
|
|
|
|
380,582
|
|
Accrued compensation
|
|
|
700,370
|
|
|
|
391,040
|
|
Income tax payable
|
|
|
122,657
|
|
|
|
-
|
|
Warranty reserve
|
|
|
660,000
|
|
|
|
700,000
|
|
Other accrued liabilities
|
|
|
208,983
|
|
|
|
302,482
|
|
Total current liabilities
|
|
|
2,279,277
|
|
|
|
1,820,479
|
|
Long-term debt, less current maturities
|
|
|
1,202,446
|
|
|
|
1,251,192
|
|
Total liabilities
|
|
|
3,481,723
|
|
|
|
3,071,671
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
Common stock, $0.01 par value; authorized: 13,000,000; shares
issued and outstanding: 8,133,857 and 8,114,252 at June 30, 2015,
June 30, 2014, respectively
|
|
|
81,339
|
|
|
|
81,143
|
|
Additional paid-in capital
|
|
|
13,327,320
|
|
|
|
13,217,166
|
|
Retained earnings (accumulated deficit)
|
|
|
514,672
|
|
|
|
(577,814
|
)
|
Total shareholders’ equity
|
|
|
13,923,331
|
|
|
|
12,720,495
|
|
Total liabilities and shareholders’ equity
|
|
$
|
17,405,054
|
|
|
$
|
15,792,166
|
|
|
|
|
|
|
|
|
|
Electromed, Inc.
|
|
|
|
|
|
Condensed Statements of Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
For the Twelve Months Ended
|
|
|
June 30,
|
|
June 30,
|
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenues
|
|
$
|
5,199,146
|
|
|
$
|
4,612,286
|
|
|
$
|
19,408,385
|
|
|
$
|
15,487,875
|
|
Cost of revenues
|
|
|
1,453,819
|
|
|
|
1,377,302
|
|
|
|
5,808,158
|
|
|
|
4,853,873
|
|
Gross profit
|
|
|
3,745,327
|
|
|
|
3,234,984
|
|
|
|
13,600,227
|
|
|
|
10,634,002
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative.
|
|
|
3,259,637
|
|
|
|
2,811,463
|
|
|
|
11,974,384
|
|
|
|
10,908,531
|
|
Research and development
|
|
|
78,446
|
|
|
|
61,054
|
|
|
|
315,647
|
|
|
|
466,063
|
|
Total operating expenses
|
|
|
3,338,083
|
|
|
|
2,872,517
|
|
|
|
12,290,031
|
|
|
|
11,374,594
|
|
Operating income (loss)
|
|
|
407,244
|
|
|
|
362,467
|
|
|
|
1,310,196
|
|
|
|
(740,592
|
)
|
Interest expense, net of interest income of $284, $663, $2,328 and
$12,393 respectively
|
|
|
20,226
|
|
|
|
21,011
|
|
|
|
85,710
|
|
|
|
79,002
|
|
Net income (loss) before income taxes
|
|
|
387,018
|
|
|
|
341,456
|
|
|
|
1,224,486
|
|
|
|
(819,594
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
(132,000
|
)
|
|
|
(51,000
|
)
|
|
|
(132,000
|
)
|
|
|
(469,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (loss)
|
|
$
|
255,018
|
|
|
$
|
290,456
|
|
|
$
|
1,092,486
|
|
|
$
|
(1,288,594
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
.03
|
|
|
$
|
0.04
|
|
|
$
|
.13
|
|
|
$
|
(0.16
|
)
|
Diluted
|
|
$
|
.03
|
|
|
$
|
0.04
|
|
|
$
|
.13
|
|
|
$
|
(0.16
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
8,119,638
|
|
|
|
8,114,252
|
|
|
|
8,115,595
|
|
|
|
8,114,252
|
|
Diluted
|
|
|
8,164,864
|
|
|
|
8,114,252
|
|
|
|
8,153,703
|
|
|
|
8,114,252
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Electromed, Inc.
|
|
|
|
Condensed Statements of Cash Flows
|
|
|
|
|
|
|
|
|
|
Years Ended June 30,
|
|
|
2015
|
|
2014
|
Cash Flows From Operating Activities
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
1,092,486
|
|
|
$
|
(1,288,594)
|
|
Adjustments to reconcile net income (loss) to net cash provided by
operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
613,304
|
|
|
|
567,341
|
|
Amortization of finite-life intangible assets
|
|
|
122,911
|
|
|
|
128,205
|
|
Amortization of debt issuance costs
|
|
|
19,210
|
|
|
|
18,019
|
|
Share-based compensation expense
|
|
|
110,350
|
|
|
|
82,228
|
|
Deferred income taxes
|
|
|
|
|
|
|
454,000
|
|
Loss on disposal of property and equipment and intangible assets
|
|
|
300,530
|
|
|
|
138,827
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(31,549)
|
|
|
|
2,526,776
|
|
Inventories
|
|
|
163,388
|
|
|
|
(855,902
|
)
|
Income tax receivable
|
|
|
-
|
|
|
|
538,285
|
|
Prepaid expenses and other assets
|
|
|
6,541
|
|
|
|
60,288
|
|
Accounts payable and accrued liabilities
|
|
|
384,043
|
|
|
|
(302,285)
|
|
Net cash provided by operating activities
|
|
|
2,781,214
|
|
|
|
2,067,188
|
|
|
|
|
|
|
|
|
|
|
Cash Flows From Investing Activities
|
|
|
|
|
|
|
|
|
Expenditures for property and equipment
|
|
|
(523,185
|
)
|
|
|
(895,177
|
)
|
Expenditures for finite-life intangible assets
|
|
|
(101,322)
|
|
|
|
(45,149
|
)
|
Net cash used in investing activities
|
|
|
(624,507
|
)
|
|
|
(940,326
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows From Financing Activities
|
|
|
|
|
|
|
|
|
Proceeds from long-term debt
|
|
|
|
-
|
|
|
1,300,000
|
|
Principal payments on long-term debt including capital lease
obligations
|
|
|
(46,372
|
)
|
|
|
(1,392,428)
|
|
Payments of deferred financing fees
|
|
|
(14,797
|
)
|
|
|
(35,296
|
)
|
Net cash used in financing activities
|
|
|
(61,169
|
)
|
|
|
(127,724
|
)
|
Net increase in cash
|
|
|
2,095,538
|
|
|
|
999,138
|
|
Cash
|
|
|
|
|
|
|
|
|
Beginning of period
|
|
|
1,502,702
|
|
|
|
503,564
|
|
End of period
|
|
$
|
3,598,240
|
|
|
$
|
1,502,702
|
|
View source version on businesswire.com: http://www.businesswire.com/news/home/20150915006738/en/
Copyright Business Wire 2015